MAPT and neurodegenerative disease: According to the 2018 National Institute on Aging and Alzheimer’s Association guidelines for AD, SPs and NFTs can be detected in vivo by positron emission tomography (PET) imaging with Aβ and tau tracers to differentiate dementia from other neurodegenerative diseases.